Scheme 1From: Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model Bilateral injections plan. Mice on control and erlotinib diets were injected bilaterally with SUM149 cells, but only half of the mice were co-injected in one side (left) with 10% mesenchymal stem cells (MSCs).Back to article page